Comparison of pre-treatment CYFRA 21-1 and SCC-Antigen assay in primary cervical carcinoma - A preliminary report

Journal of Obstetrics and Gynaecology

Volumn 25, Issue 5, 2005, Pages 486-488

  Puthucode Easwaran, S ^a   Naik, R ^a   Athavale, R ^a   Handley, G ^a   Lopes, A ^a   Godfrey, K ^a   Hatem, M ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LAPAROSCOPIC SURGERY; LYMPH VESSEL; MAJOR CLINICAL STUDY; METASTASIS; PILOT STUDY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATINS; LYMPHATIC METASTASIS; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 31944436045     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610500171144     Document Type: Article

References (19)

1. Bodenmuller H. 1995. The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scandinavian Journal of Clinical and Laboratory Investigation, Suppl. 221:60-66.
2. Bolger BS, Dabbas M, Lopes A, Monaghan JM. 1997. Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecologic Oncology 65:309-313.
3. Callet N, Cohen-Solal Le Nir CC, Berthelot E, Pichon MF. 1998. Cancer of the uterine cervix: Sensitivity and specificity of serum Cyfra 21.1 determinations. European Journal of Gynaecologic Oncology 19:50-56.
4. de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, Hollema H, Mourits MJ, de Vries EG, Aalders JG 1998. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biology 19:505-516
5. Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, Krans M, Aalders JG. 1990. Cancer of the uterine cervix: Sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecologic Oncology 39:186-194.
6. Gaarenstroom KN, Bonfrer JM, Kenter GG, Korse CM, Hart AA, Trimbos JB, Helmerhorst TJ. 1995. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 76:807-813.
7. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB. 2000. Can initial serum Cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecologic Oncology 77:164-170.
8. Hale RJ, Ryder WD, Wilcox FL, Buckley CH, Tindall VR. 1992. Cervical carcinoma: A hazard model in early stage disease. International Journal of Gynecologic Cancer 2:79-82.
9. Kainz C, Sliutz G, Mustafa G, Bieglmayr C, Koelbl H, Reinthaller A, Gitsch G. 1995. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Gynecologic Oncology 56:402-405.
10. Kamura T, Tsukamoto N, Tsuruchi N, Saito T, Matsuyama T, Akazawa K, Nakano H. 1992. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy. Cancer 69:181-186.
11. Kato H, Torigoe T. 1977. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40:1621-1628.
12. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S. 2004. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Research 64:1751-1756.
13. Logue JP, Hale RJ, Wilcox FL, Hunter RD, Buckley CH, Tindall VR. 1992. Carcinoma of the cervix: An analysis of prognostic factors, treatment and patterns of failure following Wertheims hysterectomy International Journal of Gynecologic Cancer 2:323-327.
14. Nasu K, Etoh Y, Yoshimatsu J, Matsu T, Narahara H, Miyakawa I. 1996. Serum levels of cytokeratin 19 fragments in cervical cancer Gynecology and Obstetric Investigation 42:267-270.
15. Pras E, Willemse PH, Canrinus AA, de Bruijn HW, Sluiter WJ, ten Hoor KA, Aalders JG, Szabo BG, de Vries EG. 2002. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. International Journal of Radiation Oncology Biology and Physics 52:23-32.
16. Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE. 1993. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: Prediction of response and recurrence. American Journal of Obstetrics and Gynecology 168(3 Pt 1):942-946.
17. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A. 1993. CYFRA 21-1 - a new marker in lung cancer. Cancer 72:707-713.
18. Suzuki Y, Nakano T, Ohno T, Abe A, Morita S, Tsujii H 2000. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. Journal of Cancer Research in Clinical Oncology 126:332-336.
19. Tsai SC, Kao CH, Wang SJ. 1996. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Neoplasma 43:27-29.